The B7 family and cancer therapy: costimulation and coinhibition.
about
MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytesImmune Regulation and Antitumor Effect of TIM-1Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell CarcinomaDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsThe optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translationCrystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2Molecular Insights into γδ T Cell Costimulation by an Anti-JAML AntibodyCross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentCloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activationCancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.Immune Checkpoint in Glioblastoma: Promising and ChallengingHarnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.Vaccines against human carcinomas: strategies to improve antitumor immune responses.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceInhibitors of B7-CD28 costimulation in urologic malignancies.Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro.Trends in cancer immunotherapySerum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stageAbrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic moleculeImmunotherapy for metastatic solid cancersNovel diagnostic biomarkers for prostate cancer.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerTumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patientsImmunotherapy for lung cancers.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Combinations of immunotherapy and radiation in cancer therapy.Structure and cancer immunotherapy of the B7 family member B7xClinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation.An autoimmune-mediated strategy for prophylactic breast cancer vaccination.Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccineLimited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phaseB7-h1 expressed by activated CD8 T cells is essential for their survival.Enhancement of suboptimal CD8 cytotoxic T cell effector function in vivo using antigen-specific CD80 defective T cells.Immunosuppressive tumor microenvironment in cervical cancer patientsExpression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.Autoimmune mediated regulation of ovarian tumor growth.
P2860
Q24644382-13ACC207-2A98-4D4E-BDD9-9FFF3F9A1C3BQ26740298-C14B566A-0755-4B14-BEAA-CCB15B0D49E3Q26777900-28885E81-F6F2-4333-98C9-A7EC0F87D899Q27014829-4452216F-D410-460F-B0A5-F01920137266Q27024106-CEF8CAFC-54DD-453A-BDA8-A2070FE49696Q27651269-0F3210F7-EF66-40F3-81A3-A238798B5F1DQ27666534-03D4DFBF-43A0-4107-8B33-77F110ABE535Q28076294-8C68A8D6-BCEA-41E2-AD1F-E8DC2A60B2ECQ28743206-C6EBC4C1-ACA5-4272-8841-31AE570142CDQ33648621-977B3534-8BC8-4CB1-B97F-89225F45FF64Q33650058-80F971C3-392B-4808-9BB5-C4DEB69D6362Q33687221-2F2F047F-7FF2-4C16-876D-4F2E1C00B7F7Q33734281-9E8F7593-7247-41E4-8665-98590A1E2FD1Q33823499-97E3A09C-C28B-42CA-A747-AE288141AD4EQ33827752-6D2EF9FB-C826-4BCE-953F-8DEB5EB916DDQ34028415-D540386C-0396-4AF8-A6D6-D3C5850E095DQ34052702-F7A749E0-F808-44A8-8159-379A23884127Q34052745-C222F21F-65A8-4959-9148-13FCDDD26BBCQ34162136-D1040994-9547-4CEC-9CB2-88930529B220Q34173426-9AE71A8A-5D52-410B-96EC-D1FA3F77091DQ34219970-9EBCD676-D76E-41D8-8A86-209ACF04CF82Q34231678-C8D1F354-73F8-4E9E-A0C2-CE691F66A84DQ34270064-5FF83DD2-D5F7-4854-8498-E41FCFA28D49Q34291894-FFA003A8-CB78-4216-885B-8825F0275D17Q34538321-D341564B-A4BF-413D-911E-11633292E90CQ34557611-7B892E9F-CD95-48E6-B5C9-E67D8E880083Q34577158-30AB4BCA-6F52-4DE2-8658-028C4F88CD61Q34582640-ED841E9F-D979-444A-956C-8C6EF49B1E6CQ34605921-9E05256B-78F2-4688-A4AF-22296781F24EQ34658452-3FAB2F26-DAD6-4B8E-A38C-D8140B34326DQ34809019-F8F5F520-305B-4B6A-9B52-8C65FFE0E711Q34903504-B53B7ED6-F61A-4D7F-A0C4-8B4C698F33C9Q34985115-172148F0-C14F-4261-A6F3-5271EF644920Q35130450-64880FEA-3DA4-4A9D-840B-D52B3EB5EE35Q35407260-7B6E3724-1E90-418E-940E-BC0A0021CFCDQ35566744-01774F2B-65A6-4BD2-B897-A08C3968E841Q35580588-4DFB6E4E-BC68-4815-A5AA-0D2553548CDAQ35603131-1E4AE4FB-3023-40CD-A325-7BD4F3CABC11Q35613102-49361E12-19EF-4FFD-A9D8-3440A9101DA5Q35673346-3C98154C-10FF-49EF-9C9E-E7503D3E8CD5
P2860
The B7 family and cancer therapy: costimulation and coinhibition.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The B7 family and cancer therapy: costimulation and coinhibition.
@en
type
label
The B7 family and cancer therapy: costimulation and coinhibition.
@en
prefLabel
The B7 family and cancer therapy: costimulation and coinhibition.
@en
P1476
The B7 family and cancer therapy: costimulation and coinhibition.
@en
P2093
Xingxing Zang
P304
P356
10.1158/1078-0432.CCR-07-1030
P407
P433
P577
2007-09-01T00:00:00Z